Rare Neurodegenerative Disease Treatment Market
Rare Neurodegenerative Disease Treatment Market Study by Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Acute Migraine, Autism, Narcolepsy, ALS, ADHD, and Others from 2023 to 2033
Analysis of Rare Neurodegenerative Disease Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Rare Neurodegenerative Disease Treatment Market Outlook (2023 to 2033)
Currently, the global rare neurodegenerative disease treatment market accounts for a valuation of US$ 72.9 billion and is forecasted to reach US$ 119.2 billion by the end of 2033, expanding steadily at 5% CAGR over the next ten years.
Neurodegenerative disorders, also known as degeneration nerve diseases are caused by the progressive loss of function or structure of neurons. Some of the most commonly known neurodegenerative ailments are Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), etc.
Cures for the aforementioned rare neurodegenerative diseases are very sparse and for most of these diseases, there are no definite treatments available, which has led to rising research activity to discover and develop new treatment approaches. Increasing investments in research and development of novel therapeutics and supportive initiatives by governments to promote the same are expected to primarily boost rare neurodegenerative disease treatment market growth in the future.
Rising geriatric population, growing healthcare expenditure, increasing research activity, rising awareness among the general population, growing medical tourism, increasing number of product approvals by regulatory authorities, and rising popularity of precision medicine are other prospects that could potentially boost sales of rare neurodegenerative disease therapeutics and drugs going forward.
The Asia Pacific regional market is projected to emerge as the most remunerative market for key rare neurodegenerative disease treatment providers owing to increasing investments in healthcare infrastructure development and rising awareness regarding rare genetic disorders.
Contrastingly, the high costs of rare neurodegenerative disease treatment products and therapies are projected to influentially hamper overall market evolution in the long run. The treatments available for genetic disorders and rare diseases are still in their nascent stages, which creates uncertainty over their long-term effects on patients and hence acts as a major challenge for established as well as aspiring rare neurodegenerative disease treatment providers in the global landscape over the coming years.
An elaborative assessment of product standards, safety regulations, quality control, and other factors have been mentioned in this newly updated rare neurodegenerative disease treatment research study by Fact.MR, a market research and competitive intelligence provider.
Report Attributes |
Details |
|
Rare Neurodegenerative Disease Treatment Market Size (2023) |
US$ 72.9 Billion |
|
Projected Market Value (2033F) |
US$ 119.2 Billion |
|
Global Market Growth Rate (2023 to 2033) |
5% CAGR |
|
Dominant Regional Market (2023) |
North America |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Key Factor is Aiding Rare Neurodegenerative Disease Treatment Market Growth?
“Rising Investments in Healthcare Research”
The prevalence of chronic disorders and rare diseases has increased noticeably in recent years and this has led to heightened demand for novel treatments and therapeutics to treat the aforementioned diseases. Supportive government initiatives and rising investments from the private sector to bolster research and development of novel treatments are influentially driving rare neurodegenerative disease treatment demand. Increasing awareness regarding rare genetic disorders among the general population is also expected to spur the sales of rare neurodegenerative treatment drugs in the future.
Collaborative efforts by government organizations and private companies to hasten the development of new treatment procedures and aid research scientists around the world are also expected to foster the rare neurodegenerative disease treatment market development across the forecast period.
- In September 2022, the National Institutes of Health (NIH) and the United States Food and Drug Administration (FDA) announced the launch of a private-public partnership to facilitate a better understanding of rare neurodegenerative disorders and promote the development of novel treatments for them. The partnership is called the Critical Path for Rare Neurodegenerative Diseases (CP-RND).
How Can New Entrants Penetrate This Competitive Market?
“Start-ups Penetrating the Industry by Creating Novel Therapeutics and Raising Funds to Bolster Research”
Upcoming rare neurodegenerative disease treatment providers are focusing on raising new capital to finance their research efforts and accelerate the launch of their novel therapies and treatments for rare diseases.
- In November 2022, Cajal Neuroscience, a Seattle-based start-up announced that it had raised US$ 96 million in a capital raise round. The company is specifically working on rare disorders such as Parkinson’s disease and Alzheimer’s disease. The company focuses on finding data on the neurodegeneration process and how genes affect the same.
- In September 2021, Neuroglee Therapeutics, a digital therapeutics start-up for people affected with neurodegenerative diseases announced that it had raised US$ 10 million in a Series A finance round that was led by EDBI and Openspace Ventures. The new funding was expected to be used for the launch of new virtual neurology clinics and to support the company’s move to Boston.
- ParaMag Biosciences, a new company is focusing on commercializing new technologies for the treatment of Alzheimer’s disease and other neurodegenerative ailments developed by researchers at UC Davis Health. Professor John Voss is leading the research and is working on protein misfolding to treat the aforementioned neurodegenerative diseases.
This new rare neurodegenerative disease treatment market research report by Fact.MR proffers a comprehensive assessment of how new developments by start-ups are influencing product standards and pricing trends on a global level.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
Which Country is Leading Market Growth in North America?
“United States to Spearhead Regional Market Development”
The frequent launch of new treatment drugs and therapies coupled with the presence of a developed healthcare infrastructure creates a highly opportunistic market scenario for rare neurodegenerative disease treatment providers in the United States. The presence of key biopharmaceutical companies, increasing research activity, and increasing approvals for new treatment products are other aspects that could potentially augment market development going forward.
Moreover, increasing awareness regarding the symptoms of neurodegenerative disorders and growing senescent population are also expected to promote sales of rare neurodegenerative disease treatment drugs and therapeutics in the country through 2033.
What Makes Japan an Investment-worthy Market?
“High Geriatric Population Driving Rare Neurodegenerative Disease Treatment Demand”
The rapidly aging population of Japan is a prime factor that is anticipated to bolster demand for rare neurodegenerative disease treatment in the country throughout the forecast period. Elder people are more at risk of contracting neurodegenerative disorders and as their population increases, it is projected to boost investments in research and development of novel neurological disorder therapeutics and treatments in Japan.
Rising awareness regarding dementia, a high focus on healthcare research, supportive government initiatives, and growing investments in medical infrastructure development are other factors that could potentially bolster market development in Japan through 2033.
- In February 2021, researchers at Okayama University in Japan discovered that stem cells have therapeutic capabilities to treat neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), which currently has no definite cure.
What is the Demand Outlook for Rare Neurodegenerative Disease Treatment in European Countries?
“Rising Incidence of Neurodegenerative Disorders Driving Sales of Neurological Disorder Treatment Drugs”
European countries have witnessed a notable increase in the prevalence of neurodegenerative disorders among their population in recent years, which has subsequently driven the demand for novel treatments and therapeutics for the aforementioned disorders.
Rising investments in research and development of advanced treatments and supportive government initiatives to bolster healthcare infrastructure development are other factors that are anticipated to uplift rare neurodegenerative disease treatment demand in European countries such as Germany, France, and the United Kingdom over the next ten years.
Category-wise Insights
Which Diseases Account for High Demand for Rare Neurodegenerative Disease Treatment?
“Alzheimer’s Disease & Parkinson’s Disease Leading Market Growth”
Based on indication, the rare neurodegenerative disease treatment market is segmented into multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, acute migraine, autism, narcolepsy, Amyotrophic Lateral Sclerosis (ALS), Attention Deficit Hyperactivity Disorder (ADHD), spinal muscular atrophy, Tourette syndrome, Huntington’s disease, and others.
Alzheimer’s disease is one of the most commonly known neurodegenerative disorders that affect several people across the world and is projected to prominently influence demand for neurodegenerative disease treatment over the coming years. Alzheimer’s disease mostly causes dementia and affects the older population of more than 60 years. The expanding geriatric population on a global level is projected to bolster demand for the treatment of Alzheimer’s disease, Parkinson’s disease, etc. over the coming years.
- As per the statistics published on the Alzheimer’s Disease International website, more than 55 million individuals were living with dementia in the year 2020.
Increasing awareness regarding the aforementioned neurodegenerative diseases coupled with advancements in the medical industry is predicted to offer lucrative growth scope for rare disease treatment providers.
Competitive Landscape :
Prime rare neurodegenerative disease treatment providers are focusing on expanding their business scope through the launch of new services and products.
- In July 2022, Labcorp, a renowned clinical services organization announced the launch of its first blood test to identify and confirm the symptoms of various neurodegenerative disorders such as Parkinson’s, ALS dementia, etc. It achieves this by tracking the neurofilament light chain (NfL), which is a particular protein found in the bloodstream.
More insights about new developments by leading rare neurodegenerative disease treatment companies and how they alter future pricing trends have been discussed in detail in this revised Fact.MR research analysis.
Rare Neurodegenerative Disease Treatment Industry Research Segments
-
By Indication :
- Multiple Sclerosis
- Alzheimer’s Disease
- Parkinson’s Disease
- Acute Migraine
- Autism
- Narcolepsy
- Amyotrophic Lateral Sclerosis (ALS)
- Attention Deficit Hyperactivity Disorder (ADHD)
- Spinal Muscular Atrophy
- Tourette Syndrome
- Huntington’s Disease
- Others
-
By Drug Class :
- Neurotransmitter Agents
- Neuroprotective Agents
- Biologics
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
1. Executive Summary 1.1. Summary of Key Findings 1.2. Summary of Statistics 1.3. Fact.MR Analysis and Recommendations 2. Market Overview 2.1. Market Introduction 2.2. Market Definition 2.3. Market Taxonomy 3. Market Risks & Trends Assessment 3.1. COVID-19 Impact Benchmark with Previous Crisis 3.1.1. Change in Demand and Consumption Growth 3.1.2. Before and After COVID-19 Crisis (Projected) 3.1.3. Before and after SARS Pandemic (Actual) 3.1.4. Before and After Sub-prime Crisis – 2008 (Actual) 3.1.5. Change in Demand post Recovery Period (After Each Crisis) 3.2. Impact on Market Value (US$ Mn) 3.2.1. Likely Loss of Value in 2020 3.2.2. Mid-term and Long-Term Forecast 3.2.3. Quarter by Quarter Dip and Recovery Assessment 3.3. Anticipated Demand and Value Recovery Curve 3.3.1. Likelihood of U-Shape Recovery 3.3.2. Likelihood of L-Shape Recovery 3.4. Recovery Period Assessment by Key Countries 4. Market Background and Associated Industry Indicators 4.1. Global Pharmaceutical Industry Outlook 4.1.1. Key Trends in Pharmaceuticals Market 4.1.2. Pharmaceuticals Market, by Region 4.1.3. Pharmaceuticals Market, by Competition 4.2. Forecast Factors - Relevance & Impact for Rare Neurodegenerative Disease Treatment 4.2.1. Key Market Players Historic Growth 4.2.2. Pharmaceutical Industry Growth Outlook 4.2.3. Others 4.3. Value Chain Analysis and Operating Margins 4.3.1. List of Raw Material Suppliers 4.3.2. List of Key Manufacturers 4.3.3. List of End-users 4.3.4. Profit Margins 4.3.5. Notes on Value Added at Each Node in the Value Chain 4.4. Market Dynamics 4.4.1. Drivers 4.4.2. Restraints and Market Risks 4.4.3. Opportunity Analysis 5. Global Market Demand Analysis 2018-2022 and Forecast, 2023-2033 5.1. Historical Market Analysis, 2018-2022 5.2. Current and Future Market Projections, 2023-2033 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Global Market - Pricing Analysis 6.1. Regional Pricing Analysis 6.2. Pricing Break-up 6.3. Global Average Pricing Analysis Benchmark 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2018-2022 and Forecast, 2023-2033 7.1. Historical Market Value (US$ Mn) Analysis, 2018-2022 7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) and Analysis by Indication, 2018 - 2022 8.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Indication, 2023 - 2033 8.3.1. Multiple Sclerosis 8.3.2. Alzheimer’s Disease 8.3.3. Parkinson Disease 8.3.4. Acute Migraine 8.3.5. Autism 8.3.6. Narcolepsy 8.3.7. Amyotrophic Lateral Sclerosis (ALS) 8.3.8. Attention Deficit Hyperactivity Disorder (ADHD) 8.3.9. Spinal Muscular Atrophy 8.3.10. Tourette Syndrome 8.3.11. Huntington’s Disease 8.3.12. Others 8.4. Market Attractiveness Analysis by Indication 9. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) and Analysis by Drug Class, 2018 - 2022 9.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Drug Class, 2023 - 2033 9.3.1. Neurotransmitter Agents 9.3.2. Neuroprotective Agents 9.3.3. Biologics 9.3.4. Others 9.4. Market Attractiveness Analysis by Drug Class 10. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) and Analysis by Distribution Channel, 2018 - 2022 10.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Distribution Channel, 2023 - 2033 10.3.1. Hospital Pharmacies 10.3.2. Online Pharmacies 10.3.3. Retail Pharmacies 10.4. Market Attractiveness Analysis by Distribution Channel 11. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) and Analysis by Region, 2018 - 2022 11.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Region, 2020 – 2028 11.3.1. North America 11.3.2. Europe 11.3.3. Asia Pacific 11.3.4. Latin America 11.3.5. Middle East & Africa 12. North America Market Analysis 2018-2022 and Forecast 2023-2033 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2018 - 2022 12.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2023 - 2033 12.4.1. By Country 12.4.1.1. U.S. 12.4.1.2. Canada 12.4.2. By Indication 12.4.3. By Drug Class 12.4.4. By Distribution Channel 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Indication 12.5.3. By Drug Class 12.5.4. By Distribution Channel 12.6. Market Trends 12.7. Key Market Participants - Intensity Mapping 12.8. Drivers and Restraints - Impact Analysis 13. Europe Market Analysis 2018-2022 and Forecast 2023-2033 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2018 - 2022 13.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2023 - 2033 13.4.1. By Country 13.4.1.1. Germany 13.4.1.2. U.K. 13.4.1.3. France 13.4.1.4. Spain 13.4.1.5. Italy 13.4.1.6. Rest of Europe 13.4.2. By Indication 13.4.3. By Drug Class 13.4.4. By Distribution Channel 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Indication 13.5.3. By Drug Class 13.5.4. By Distribution Channel 13.6. Market Trends 13.7. Key Market Participants - Intensity Mapping 13.8. Drivers and Restraints - Impact Analysis 14. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2018 - 2022 14.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2023 - 2033 14.4.1. By Country 14.4.1.1. Japan 14.4.1.2. China 14.4.1.3. India 14.4.1.4. Australia & New Zealand 14.4.1.5. Rest of Asia Pacific 14.4.2. By Indication 14.4.3. By Drug Class 14.4.4. By Distribution Channel 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Indication 14.5.3. By Drug Class 14.5.4. By Distribution Channel 14.6. Market Trends 14.7. Key Market Participants - Intensity Mapping 14.8. Drivers and Restraints - Impact Analysis 15. Latin America Market Analysis 2018-2022 and Forecast 2023-2033 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2018 - 2022 15.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2023 - 2033 15.4.1. By Country 15.4.1.1. Brazil 15.4.1.2. Mexico 15.4.1.3. Rest of Latin America 15.4.2. By Indication 15.4.3. By Drug Class 15.4.4. By Distribution Channel 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Indication 15.5.3. By Drug Class 15.5.4. By Distribution Channel 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 16. Middle East and Africa Market Analysis 2018-2022 and Forecast 2023-2033 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2018 - 2022 16.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2023 - 2033 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. South Africa 16.4.1.3. Rest of Middle East and Africa 16.4.2. By Indication 16.4.3. By Drug Class 16.4.4. By Distribution Channel 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Indication 16.5.3. By Drug Class 16.5.4. By Distribution Channel 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 17. Key Countries Market Analysis 2018-2022 and Forecast 2023-2033 17.1. Introduction 17.1.1. Market Value Proportion Analysis, By Key Countries 17.1.2. Global Vs. Country Growth Comparison 17.2. U.S. Market Analysis 17.2.1. Pricing Analysis 17.2.2. Market Value Proportion Analysis by Market Taxonomy 17.2.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.2.3.1. By Indication 17.2.3.2. By Drug Class 17.2.3.3. By Distribution Channel 17.3. Canada Market Analysis 17.3.1. Pricing Analysis 17.3.2. Market Value Proportion Analysis by Market Taxonomy 17.3.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.3.3.1. By Indication 17.3.3.2. By Drug Class 17.3.3.3. By Distribution Channel 17.4. Germany Market Analysis 17.4.1. Pricing Analysis 17.4.2. Market Value Proportion Analysis by Market Taxonomy 17.4.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.4.3.1. By Indication 17.4.3.2. By Drug Class 17.4.3.3. By Distribution Channel 17.5. U.K. Market Analysis 17.5.1. Pricing Analysis 17.5.2. Market Value Proportion Analysis by Market Taxonomy 17.5.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.5.3.1. By Indication 17.5.3.2. By Drug Class 17.5.3.3. By Distribution Channel 17.6. France Market Analysis 17.6.1. Pricing Analysis 17.6.2. Market Value Proportion Analysis by Market Taxonomy 17.6.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.6.3.1. By Indication 17.6.3.2. By Drug Class 17.6.3.3. By Distribution Channel 17.7. Spain Market Analysis 17.7.1. Pricing Analysis 17.7.2. Market Value Proportion Analysis by Market Taxonomy 17.7.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.7.3.1. By Indication 17.7.3.2. By Drug Class 17.7.3.3. By Distribution Channel 17.8. Italy Market Analysis 17.8.1. Pricing Analysis 17.8.2. Market Value Proportion Analysis by Market Taxonomy 17.8.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.8.3.1. By Indication 17.8.3.2. By Drug Class 17.8.3.3. By Distribution Channel 17.9. Japan Market Analysis 17.9.1. Pricing Analysis 17.9.2. Market Value Proportion Analysis by Market Taxonomy 17.9.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.9.3.1. By Indication 17.9.3.2. By Drug Class 17.9.3.3. By Distribution Channel 17.10. China Market Analysis 17.10.1. Pricing Analysis 17.10.2. Market Value Proportion Analysis by Market Taxonomy 17.10.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.10.3.1. By Indication 17.10.3.2. By Drug Class 17.10.3.3. By Distribution Channel 17.11. India Market Analysis 17.11.1. Pricing Analysis 17.11.2. Market Value Proportion Analysis by Market Taxonomy 17.11.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.11.3.1. By Indication 17.11.3.2. By Drug Class 17.11.3.3. By Distribution Channel 17.12. Australia & New Zealand Market Analysis 17.12.1. Pricing Analysis 17.12.2. Market Value Proportion Analysis by Market Taxonomy 17.12.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.12.3.1. By Indication 17.12.3.2. By Drug Class 17.12.3.3. By Distribution Channel 17.13. Brazil Market Analysis 17.13.1. Pricing Analysis 17.13.2. Market Value Proportion Analysis by Market Taxonomy 17.13.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.13.3.1. By Indication 17.13.3.2. By Drug Class 17.13.3.3. By Distribution Channel 17.14. Brazil Market Analysis 17.14.1. Pricing Analysis 17.14.2. Market Value Proportion Analysis by Market Taxonomy 17.14.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.14.3.1. By Indication 17.14.3.2. By Drug Class 17.14.3.3. By Distribution Channel 17.15. Mexico Market Analysis 17.15.1. Pricing Analysis 17.15.2. Market Value Proportion Analysis by Market Taxonomy 17.15.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.15.3.1. By Indication 17.15.3.2. By Drug Class 17.15.3.3. By Distribution Channel 17.16. GCC Countries Market Analysis 17.16.1. Pricing Analysis 17.16.2. Market Value Proportion Analysis by Market Taxonomy 17.16.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.16.3.1. By Indication 17.16.3.2. By Drug Class 17.16.3.3. By Distribution Channel 17.17. South Africa Market Analysis 17.17.1. Pricing Analysis 17.17.2. Market Value Proportion Analysis by Market Taxonomy 17.17.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 17.17.3.1. By Indication 17.17.3.2. By Drug Class 17.17.3.3. By Distribution Channel 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies (Rare Neurodegenerative Disease Treatment) 18.2. Market Concentration 18.3. Market Share Analysis of Top Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. Allergan Plc 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Profitability by Market Segments (Product/Region) 19.3.1.4. Sales Footprint 19.3.1.5. Strategy Overview 19.3.2. Bayer AG 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Profitability by Market Segments (Product/Region) 19.3.2.4. Sales Footprint 19.3.2.5. Strategy Overview 19.3.3. F. Hoffmann-La Roche Ltd. 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Profitability by Market Segments (Product/Region) 19.3.3.4. Sales Footprint 19.3.3.5. Strategy Overview 19.3.4. GlaxoSmithKline Plc 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Profitability by Market Segments (Product/Region) 19.3.4.4. Sales Footprint 19.3.4.5. Strategy Overview 19.3.5. Johnson & Johnson 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Profitability by Market Segments (Product/Region) 19.3.5.4. Sales Footprint 19.3.5.5. Strategy Overview 19.3.6. Merck KGaA 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Profitability by Market Segments (Product/Region) 19.3.6.4. Sales Footprint 19.3.6.5. Strategy Overview 19.3.7. Novartis AG 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Profitability by Market Segments (Product/Region) 19.3.7.4. Sales Footprint 19.3.7.5. Strategy Overview 19.3.8. Pfizer Inc. 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Profitability by Market Segments (Product/Region) 19.3.8.4. Sales Footprint 19.3.8.5. Strategy Overview 19.3.9. Sanofi 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Profitability by Market Segments (Product/Region) 19.3.9.4. Sales Footprint 19.3.9.5. Strategy Overview 19.3.10. Teva Pharmaceuticals Industries Ltd. 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Profitability by Market Segments (Product/Region) 19.3.10.4. Sales Footprint 19.3.10.5. Strategy Overview 20. Assumptions and Acronyms Used 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 02: Global Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 03: Global Market Value (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 04: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 05: Global are Neurodegenerative Disease Treatment Market Value (US$ Mn) Forecast, by Region, 2023–2033
Table 06: North America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 07: North America Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 08: North America Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 09: North America Market Value (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 10: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 11: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 12: Europe Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 13: Europe Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 14: Europe Market Value (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 15: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 16: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 17: Asia Pacific Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 18: Asia Pacific Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 19: Asia Pacific Market Value (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 20: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 21: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 22: Latin America Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 23: Latin America Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 24: Latin America Market Value (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 25: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 26: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 27: Middle East & Africa Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 28: Middle East & Africa Market Value (US$ Mn) Forecast, by Indication, 2023–2033
Table 29: Middle East & Africa Market Value (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 30: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Forecast, 2023–2033
Figure 02: Global Market Value Share, by Indication, 2023
Figure 03: Global Market Value Share, by Drug Class, 2023
Figure 04: Global Market Value Share, by Distribution Channel, 2023
Figure 05: Global Market Value Share, by Region, 2023
Figure 06: Global Rare Neurodegenerative Disease Market Value Share Analysis, by Indication, 2023 and 2033
Figure 07: Global Rare Neurodegenerative Disease Market Attractiveness Analysis, by Indication, 2023–2033
Figure 08: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Multiple Sclerosis (MS), 2023–2033
Figure 09: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Alzheimer’s Disease, 2023–2033
Figure 10: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Parkinson's Disease, 2023–2033
Figure 11: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Acute Migraine, 2023–2033
Figure 12: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Autism, 2023–2033
Figure 13: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Narcolepsy, 2023–2033
Figure 14: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Amyotrophic Lateral Sclerosis (ALS), 2023–2033
Figure 15: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Attention Deficit Hyperactivity Disorder (ADHD), 2023–2033
Figure 16: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Spinal Muscular Atrophy, 2023–2033
Figure 17: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Tourette Syndrome, 2023–2033
Figure 18: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Huntington's disease, 2023–2033
Figure 19: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Others, 2023–2033
Figure 20: Global Rare Neurodegenerative Disease Market Value Share Analysis, by Drug Class, 2023 and 2033
Figure 21: Global Rare Neurodegenerative Disease Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 22: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Neuroprotective Agents, 2023–2033
Figure 23: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Neurotransmitter Agents, 2023–2033
Figure 24: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Biologics, 2023–2033
Figure 25: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Others, 2023–2033
Figure 26: Global Rare Neurodegenerative Disease Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 27: Global Rare Neurodegenerative Disease Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 28: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Hospital Pharmacies, 2023–2033
Figure 29: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Online Pharmacies, 2023–2033
Figure 30: Global Rare Neurodegenerative Disease Market Value (US$ Mn), by Retail Pharmacies, 2023–2033
Figure 31: Global Rare Neurodegenerative Disease Market Value Share Analysis, by Region, 2023 and 2033
Figure 32: Global Rare Neurodegenerative Disease Market Attractiveness Analysis, by Region, 2023–2033
Figure 33: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 34: North America Market Attractiveness Analysis, by Country, 2023 and 2033
Figure 35: North America Market Value Share Analysis, by Country, 2023–2033
Figure 36: North America Market Value Share Analysis, by Indication, 2023 and 2033
Figure 37: North America Market Attractiveness Analysis, by Indication, 2023–2033
Figure 38: North America Market Value Share Analysis, by Drug Class, 2023 and 2033
Figure 39: North America Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 40: North America Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 41: North America Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 42: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 43: Europe Market Attractiveness Analysis, by Country/Sub-region, 2023 and 2033
Figure 44: Europe Market Value Share Analysis, by Country/Sub-region, 2023–2033
Figure 45: Europe Market Value Share Analysis, by Indication, 2023 and 2033
Figure 46: Europe Market Attractiveness Analysis, by Indication, 2023–2033
Figure 47: Europe Market Value Share Analysis, by Drug Class, 2023 and 2033
Figure 48: Europe Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 49: Europe Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 50: Europe Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 51: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 52: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2023 and 2033
Figure 53: Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2023–2033
Figure 54: Asia Pacific Market Value Share Analysis, by Indication, 2023 and 2033
Figure 55: Asia Pacific Market Attractiveness Analysis, by Indication, 2023–2033
Figure 56: Asia Pacific Market Value Share Analysis, by Drug Class, 2023 and 2033
Figure 57: Asia Pacific Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 58: Asia Pacific Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 59: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 60: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 61: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2023 and 2033
Figure 62: Latin America Market Value Share Analysis, by Country/Sub-region, 2023–2033
Figure 63: Latin America Market Value Share Analysis, by Indication, 2023 and 2033
Figure 64: Latin America Market Attractiveness Analysis, by Indication, 2023–2033
Figure 65: Latin America Market Value Share Analysis, by Drug Class, 2023 and 2033
Figure 66: Latin America Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 67: Latin America Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 68: Latin America Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 69: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 70: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2023 and 2033
Figure 71: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2023–2033
Figure 72: Middle East & Africa Market Value Share Analysis, by Indication, 2023 and 2033
Figure 73: Middle East & Africa Market Attractiveness Analysis, by Indication, 2023–2033
Figure 74: Middle East & Africa Market Value Share Analysis, by Drug Class, 2023 and 2033
Figure 75: Middle East & Africa Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 76: Middle East & Africa Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 77: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 78: Global Market Share Analysis, by Company, 2023
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the size of the rare neurodegenerative disease treatment market?
The global rare neurodegenerative disease treatment market stands at US$ 72.9 billion in 2023.
How big will the market for rare neurodegenerative disease treatment be by 2033?
By 2033-end, rare neurodegenerative disease treatment demand is slated to rake in revenue of US$ 119.2 billion.
At what rate is the market estimated to progress?
Over the next ten years, demand for rare neurodegenerative disease treatment is projected to rise steadily at 5% CAGR.
Which region accounts for a dominant market share?
The North American rare neurodegenerative disease treatment market accounts for a commanding share of the global landscape.
Who are the prime rare neurodegenerative disease treatment providers?
GlaxoSmithKline Plc, Bayer AG, Teva Pharmaceuticals Industries Ltd., and Novartis AG are key companies in this space.
Rare Neurodegenerative Disease Treatment Market